Amiodarone: pharmacokinetic interactions with other antiarrhythmic agents.
Amiodarone, the first-in-class antiarrhythmic agent developed in the last two decades, was the first drug to demonstrate a significant survival benefit in patients with severe ventricular arrhythmias. In contrast to older antiarrhythmic drugs, a DDI with amiodarone does not portend a poor therapeutic outcome (except in case of hypoxia 50e0806aeb gisxant
https://travellersden.co.za/ad....vert/practically-mac